Sodium-glucose cotransporter-2 (SGLT2) inhibitors have become a mainstay pharmacologic treatment of T2DM due to their demonstrated reduction in heart failure outcomes [2], and progression of chronic kidney disease [3], although the exact mechanism of cardiovascular benefit remains debated [4]. The gene discussed is SLC5A2; the disease is heart failure.